Treatment for rare leukemias gets early OK through accelerated approval program.

Effort to focus on cancer in hopes of accelerating diagnosis, improving treatment, and sparking innovation.

Generic drug giant's long-term strategy will include manufacturing revamp, move toward higher-value medicines.

The weekly round-up of failed trials, missed targets, and other business mishaps.

The Indian Patent Office has revoked Merck’s patent for an asthma drug following a challenge from domestic pharmaceutical company Cipla. In an order issued by the patent office, the drug’s patent was revoked on the grounds that it lacked invention. The decision is the latest in a string of patent revocations by Indian officials.

With FDA approval in hand, company begins taking orders for smartphone-linked device.

AliveCor has received FDA clearance for its mobile heart monitor, allowing it to open pre-sales for the device in the United States.

Limited results from a mid-stage clinical trial again force tough decisions in Menlo Park.

Geron will quit development of the experimental brain cancer therapy, GRN1005, and cut 43 related jobs as it shifts its focus to testing another drug candidate, imetelstat, as a treatment for blood cancers and some types of solid tumors. 

Biorepository will accelerate the use of the technology to enhance drug development.

Proposed act would create new Office of Wireless Health Technology within the FDA.

Congressman Mike Honda is calling for the formation of a new Office of Wireless Health Technology to be created within the U.S. Food and Drug Administration as part of a package of financial incentives, grants, and workforce development programs to advance the health information technology sector. 

As the U.S. government races toward the fiscal cliff, the lame duck Congress must reach an agreement on spending reductions and tax increases or face the trigger of $1.2 trillion in across the board budget cuts. The battle underway could have significant consequences for the life sciences industry. We spoke to David Gollaher, CEO of the California Healthcare Institute, about how sequestration will impact everything from the National Institutes of Health to the U.S. Food and Drug Administration, the likelihood of a resolution before year end, and what’s at stake for the life sciences industry.

Russian nanotech fund will invest up to $25 million as Selecta sets up Russian research center.